TY - JOUR
T1 - Clinical and biological activity of soy protein powder supplementation in healthy male volunteers
AU - Goodin, Susan
AU - Shen, Francisco
AU - Shih, Weichung J.
AU - Dave, Nisha
AU - Kane, Michael P.
AU - Medina, Patrick
AU - Lambert, George H.
AU - Aisner, Joseph
AU - Gallo, Michael
AU - DiPaola, Robert S.
PY - 2007/4
Y1 - 2007/4
N2 - Purpose: To determine if a commonly used soy protein supplement exhibits biological activity in vivo and in vitro, we evaluated an over-the-counter soy protein powder supplement using blood from healthy male volunteers and in an estrogen receptor in vitro assay. Subjects and Methods: We recruited healthy male volunteers 18 years of age or older that were in good health. Treatment consisted of consuming two scoops (56 g) of pure soy protein powder (Puritan's Pride, Oakdale, NY) daily for 28 days. Serum testosterone and luteinizing hormone (LH) levels were collected on days -7, 0, 14, and 28 of therapy, and day 42. A reporter estrogen receptor (ER) assay was used to determine the effect on ER-β and ER-α in vitro. Results: Twelve subjects were enrolled with a mean age of 32.25 years (range 25 to 47). Serum testosterone decreased 19%(±22%) during the 4-week use of soy protein powder (P = 0.021) and increased within 2 weeks after we discontinued soy protein powder. Serum LH concentrations decreased during the 4-week use of soy protein powder then increased within 2 weeks after we stopped the soy protein powder, but the changes did not reach statistical significance (P = 0.20). Soy protein powder was found to induce agonist activity to ER-β using a reporter estrogen receptor assay in yeast. Conclusion: Soy protein powder decreases serum testosterone levels in healthy men and acts as an ER-β agonist; the significance of this biological effect with respect to cancer prevention needs further study.
AB - Purpose: To determine if a commonly used soy protein supplement exhibits biological activity in vivo and in vitro, we evaluated an over-the-counter soy protein powder supplement using blood from healthy male volunteers and in an estrogen receptor in vitro assay. Subjects and Methods: We recruited healthy male volunteers 18 years of age or older that were in good health. Treatment consisted of consuming two scoops (56 g) of pure soy protein powder (Puritan's Pride, Oakdale, NY) daily for 28 days. Serum testosterone and luteinizing hormone (LH) levels were collected on days -7, 0, 14, and 28 of therapy, and day 42. A reporter estrogen receptor (ER) assay was used to determine the effect on ER-β and ER-α in vitro. Results: Twelve subjects were enrolled with a mean age of 32.25 years (range 25 to 47). Serum testosterone decreased 19%(±22%) during the 4-week use of soy protein powder (P = 0.021) and increased within 2 weeks after we discontinued soy protein powder. Serum LH concentrations decreased during the 4-week use of soy protein powder then increased within 2 weeks after we stopped the soy protein powder, but the changes did not reach statistical significance (P = 0.20). Soy protein powder was found to induce agonist activity to ER-β using a reporter estrogen receptor assay in yeast. Conclusion: Soy protein powder decreases serum testosterone levels in healthy men and acts as an ER-β agonist; the significance of this biological effect with respect to cancer prevention needs further study.
UR - http://www.scopus.com/inward/record.url?scp=34247471221&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247471221&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-06-0882
DO - 10.1158/1055-9965.EPI-06-0882
M3 - Article
C2 - 17416779
AN - SCOPUS:34247471221
SN - 1055-9965
VL - 16
SP - 829
EP - 833
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 4
ER -